杰龙制药

最新新闻

• 评级变动
  Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2025/11/4
• 评级变动
  A Quick Look at Today's Ratings for Geron(GERN.US), With a Forecast Between $4 to $5
  \u5e02\u573a\u8d44\u8baf · 2025/8/7
• 评级变动
  Leerink Partners Maintains Geron(GERN.US) With Buy Rating, Announces Target Price $3
  \u5e02\u573a\u8d44\u8baf · 2025/7/21
• 评级变动
  Needham Maintains Geron(GERN.US) With Buy Rating, Cuts Target Price to $4
  \u5e02\u573a\u8d44\u8baf · 2025/11/6
• 评级变动
  TD Cowen Maintains Geron(GERN.US) With Buy Rating, Cuts Target Price to $3
  \u5e02\u573a\u8d44\u8baf · 2026/1/29
• 公司公告
  Geron | 4: Statement of changes in beneficial ownership of securities-Director O'Farrell Elizabeth G.
  SEC · 2026/5/27
• 公司公告
  4: Geron | 4: Statement of changes in beneficial ownership of securities-Director Spiegel Robert J.
  SEC · 2026/7/2
• Earnings Flash (GERN) Geron Corporation Reports Q2 Revenue $57.5M, Vs. FactSet Est of $55.3M
  MT Newswires · 2026/8/5
• 评级变动
  TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2025/11/6
• Needham Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $4
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $3
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  A Quick Look at Today's Ratings for Geron(GERN.US), With a Forecast Between $1 to $4
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• H.C. Wainwright Maintains Geron(GERN.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 公司公告
  Geron | 4: Statement of changes in beneficial ownership of securities-Director Spiegel Robert J.
  SEC · 2026/10/2
• 评级变动
  Goldman Sachs Maintains Geron(GERN.US) With Sell Rating, Maintains Target Price $1
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Scotiabank Maintains Geron(GERN.US) With Hold Rating, Maintains Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/7
• 公司公告
  Geron | 4: Statement of changes in beneficial ownership of securities-Director Spiegel Robert J.
  SEC · 2026/4/2
• 公司公告
  Geron | 4: Statement of changes in beneficial ownership of securities-Director Spiegel Robert J.
  SEC · 2026/5/27
• Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Geron (GERN)
  TipRanks · 2026/4/22
• 评级变动
  TR | OpenAI - 4o Maintains Geron(GERN.US) With Hold Rating, Maintains Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/12

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。